3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Temozolomide
29
Bevacizumab
14
Radiotherapy
12
Trastuzumab
10
Lomustine
9
Capecitabine
8
paclitaxel-Angiopep-2 conjugate
6
Nivolumab
6
pembrolizumab
5
dabrafenib
5
abemaciclib
5
Radiation
5
icotinib
4
Surgical Procedures, Operative
4
Paclitaxel
4
Lapatinib
4
Irinotecan
4
Flucytosine
4
Dianhydrogalactitol
4
Corticotropin-Releasing Hormone
4
Chlorotoxin
4
Carboplatin
4
vocimagene amiretrorepvec
3
verubulin
3
tucatinib
3
osimertinib
3
motexafin gadolinium
3
XL647
3
Spermine Synthase
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Brain Neoplasms
×
gadoterate meglumine
×
Clear all
NCT06057168
2026-01-29
GDX-44-016
Guerbet
Phase 3
Completed
138 enrolled
7 charts
NCT02034708
2016-12-30
REMIND
Guerbet
Phase 4
Completed
279 enrolled
9 charts